Upstream Bio Appoints Allison Ambrose as General Counsel
December 17, 2024 08:00 ET
|
Upstream Bio
Upstream appoints Allison Ambrose as General Counsel
Upstream Bio Announces Addition to Russell 2000® Index
December 16, 2024 08:00 ET
|
Upstream Bio
Upstream Bio (Nasdaq:UPB) to be added to Russell 2000® index effective at the open of the U.S. equities market on Monday, December 23.
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 21, 2024 08:00 ET
|
Upstream Bio
Upstream Bio CEO to participate in fireside chat at Piper Sandler
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024 07:00 ET
|
Upstream Bio
Upstream reports third quarter 2024 financial results and recent corporate achievements
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 15, 2024 16:15 ET
|
Upstream Bio
Upstream closes $293 million upsized IPO including full exercise of underwriters’ option to purchase additional shares
Upstream Bio Announces Pricing of Upsized Initial Public Offering
October 10, 2024 19:35 ET
|
Upstream Bio
Upstream Bio announces pricing of upsized initial public offering
AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
October 10, 2022 12:04 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
October 10, 2022 12:04 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
November 10, 2020 16:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress
September 08, 2020 02:44 ET
|
AB Science
Paris, 08 September 2020, 7.30am AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress Abstract...